Friday, June 18, 2021
Home Industry


Welin Berger: ‘This is how we work on probiotics at Biogaia’

Katayoun Welin Berger, BioGaia's Vice President Operations, tells us about the activities of the company.

Emily Hollister: ‘From microbiome to therapeutics and diagnostics’

The microbiome may be a source for biomarkers leading to therapeutic discoveries and diagnostics. We discuss it with Emily Hollister, Vice President of Diversigen.

Richard Ellis: ‘Bringing probiotics from the lab to the market’

Richard Ellis, Head of Business Development at Biose, explains how CDMO companies assist start-ups in bringing live biotherapeutic products to the market.

Travis Whitfill: ‘We’re studying new products for skin diseases’

Travis Whitfill, Co-Founder and CSO of Azitra, explains how Staphylococcus epidermidis-based products may treat various skin conditions and diseases.

Denise Kelly: ‘2019 will be a very important year for the global microbiome market’

Probiotics: 2019 will be crucial for scientific and regulatory aspects with help coming also from Venture Capital. Denise Kelly from Seventure talks about it.

Regulation of probiotics: challenges and opportunities

The development of probiotics presents major regulatory challenges. We discussed it this Clara Desvignes from Voisin Consulting Life Sciences.

Ross Youngs: ‘We investigate the aquatic microbiome to obtain metabolites and postbiotics’

New technologies such as the analysis of the "aquatic microbiota" allow to dig deeply into the microbiome chemistry. We discuss this approach with Ross Youngs, CEO of Biosortia.

Stay in Touch

MicrobiomePost supports the microbiome community by connecting business, investors, academy, industry and science key opinion leaders.

Read more